Glycerol phenylbutyrate
| |
Clinical data | |
---|---|
Trade names | Ravicti |
AHFS/Drugs.com | ravicti |
License data | |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
ChEMBL | |
ECHA InfoCard |
100.228.552 |
Chemical and physical data | |
Formula | C33H38O6 |
Molar mass | 530.651 g/mol |
3D model (JSmol) | |
| |
|
Glycerol phenylbutyrate (USAN), trade name Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body.[1] It is an FDA-approved prescription drug in the US.[2] It is approved for anyone over 2 months of age. It was developed by Hyperion Theraputics based on the existing drug Buphenyl, and received approval on February 1, 2013.[3] Hyperion has been criticized for setting a high price for the drug. The price was set at US$250,000–290,000. In 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive Buphenyl ($113.6 million in sales).[4] In March 2015, Horizon Pharma acquired Hyperion Therapeutics and thus Raviciti.
References
- ↑ http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm337639.htm
- ↑ Drugs@FDA: FDA Approved Drug Products. Accessdata.fda.gov. [accessed 2018 Feb 18]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=203284
- ↑ Herder M. Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and Canada. Journal of Law and the Biosciences. 2016 [accessed 2018 Feb 18];3(1):158-166. DOI: 10.1093/jlb/lsv060 URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033429/
- ↑ "Horizon Pharma to Acquire Hyperion Therapeutics for $1.1B". GEN.
External links